SOMA
Pronunciation: kar-eye-soe-PROE-doel


What it isGABA-A-active central muscle relaxant; short-term relief of acute musculoskeletal pain.
Why this oneIt is the common muscle relaxant uniquely converted to the sedative meprobamate.
What limits itSedation, dependence, misuse, and withdrawal make it a Schedule IV drug best avoided when safer alternatives exist.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Acute musculoskeletal pain | Adults | 350 mg TID + QHS | 350 mg TID + QHS |
Renal Not evaluated; use caution (renally excreted; dialyzable)
Hepatic Not evaluated; use caution (hepatically metabolized)
Recommended maximum duration of use is 2–3 weeks
Available strengths
Pregnancy Decades of use without identified risk; animal data show reduced fetal survival at high doses
Lactation Present in breastmilk; monitor breastfed infant for sedation
| Strength | #/mo | generic $/mo | CostPlus | |
|---|---|---|---|---|
| 250 mg | tab | 90 TID | $42.65 | not offered |
| 350 mg | tab | 90 TID | $6.35 | not offered |
Generic entry1982
NO BOXED WARNINGS
Principal riskMetabolized to meprobamate; sedation and dependence
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Open Carisoprodol in the interactive console ↗
